ArticleProceedings (Baylor University. Medical Center)
Differential cardiometabolic outcomes of leuprolide versus spironolactone in women with polycystic ovary syndrome.
Article in Proceedings (Baylor University. Medical Center). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Polycystic ovarian syndrome-associated hyperandrogenism and metabolic dysfunction.Proceedings (Baylor University. Medical Center) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder with systemic implications including dyslipidemia, hypertension, and chronic kidney disease. We explored the metabolic effects of leuprolide and spironolactone beyond their use for managing hyperandrogenic symptoms in PCOS. Methods: We used the TriNetX Research Network to identify patients aged 18 to 50 years diagnosed with PCOS and stratified them by use of leuprolide or spironolactone. The cohorts were matched for demographics, comorbidities, and confounding medications and each had 2078 patients. Outcomes included rates of hypercholesterolemia, lipid profiles, lipid-lowering agent use, hypertension, antihypertensive medications, obesity, hyperglycemia, chronic kidney disease, and major adverse cardiovascular events. Results: Over a 5-year examination period, leuprolide carried lower risks than spironolactone for hypercholesterolemia (risk ratio [RR] 0.46; 95% confidence interval [CI], 0.39-0.54), low high-density lipoprotein (RR 0.41; CI, 0.35-0.48), and elevated low-density lipoprotein (RR 0.39; CI, 0.26-0.58). Risks were also reduced for hypertension (RR 0.73; CI, 0.61-0.87), antihypertensive use (RR 0.86; CI, 0.75-0.99), and lipid-lowering therapy (RR 0.79; CI, 0.63-0.99). No significant differences appeared for chronic kidney disease, major adverse cardiovascular events, hyperglycemia, or obesity. Conclusion: Leuprolide therapy was associated with improved lipid and hypertension outcomes compared to spironolactone. These findings support leuprolide's potential role in broader metabolic management of PCOS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.